Publication:
Safety and efficacy of diflunisal in transthyretin cardiac amyloidosis.

Simple item page
dc.contributor.authorPeiró-Aventín, Belén
dc.contributor.authorCabrera-Romero, Eva
dc.contributor.authorMora-Ayestarán, Nerea
dc.contributor.authorDomínguez, Fernando
dc.contributor.authorGonzález-López, Esther
dc.contributor.authorGarcia-Pavia, Pablo
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)es_ES
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.contributor.funderFundación ProCNICes_ES
dc.contributor.funderMinisterio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España)es_ES
dc.date.accessioned2024-07-11T14:14:30Z
dc.date.available2024-07-11T14:14:30Z
dc.date.issued2024-05
dc.description.peerreviewedSíes_ES
dc.description.sponsorshipFunding for this study has been received from the Carlos III Health Institute (grants PI18/0765 & PI20/01379). This research was co-funded by the European Regional Development Fund/ European Social Fund, ‘‘A way to make Europe’’/‘‘Investing in your future’’. The CNIC (Centro Nacional de Investigaciones Cardiovasculares) receives funding from the Carlos III Health Institute, the Ministry of Science and Innovation, and the Fundacio´n Pro-CNIC, and is a Severo Ochoa affiliate center (CEX2020-001041-S).es_ES
dc.format.number5es_ES
dc.format.page426es_ES
dc.format.volume77es_ES
dc.identifier.citationRev Esp Cardiol. 2024 May;77(5):426-428.es_ES
dc.identifier.doi10.1016/j.rec.2023.10.016es_ES
dc.identifier.e-issn1885-5857es_ES
dc.identifier.journalRevista espanola de cardiologia (English ed.)es_ES
dc.identifier.pubmedID38325700es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/20518
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PI18/0765es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PI20/01379es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/CEX2020-001041-Ses_ES
dc.relation.publisherversion10.1016/j.rec.2023.10.016es_ES
dc.repisalud.institucionCNICes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Miocardiopatías Hereditariases_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshAmyloid Neuropathies, Familiales_ES
dc.subject.meshDiflunisales_ES
dc.subject.meshCardiomyopathieses_ES
dc.subject.meshHumanses_ES
dc.subject.meshMalees_ES
dc.subject.meshFemalees_ES
dc.subject.meshAgedes_ES
dc.subject.meshTreatment Outcomees_ES
dc.subject.meshMiddle Agedes_ES
dc.titleSafety and efficacy of diflunisal in transthyretin cardiac amyloidosis.es_ES
dc.typeotheres_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication52ada1ee-7241-4738-b46d-90a5ccc14894
relation.isAuthorOfPublication.latestForDiscovery52ada1ee-7241-4738-b46d-90a5ccc14894

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Safety and efficacy_Rev Esp Cardiol_2024.pdf
Size:
251.2 KB
Format:
Adobe Portable Document Format
Description:
Letter
Download

Collections

Grupos de investigación